FINWIRES · TerminalLIVE
FINWIRES

Diageo's Sales Growth Outlook is Prudent, RBC Capital Markets Says

By

Diageo's (DEO) plan to revive sales growth through cost savings and a comprehensive retooling of the organization is credible, with a sustained increase in return on invested capital potentially supporting the share price, RBC Capital Markets said in a Monday note.

The firm said the plan does not envisage a margin reset, with management instead expecting cost savings and organizational changes to provide the resources needed to revive sales growth.

RBC estimated that adverse geographic mix, price investment, revenue management and the shift to ready-to-drink products could depress margins by around 2 percentage points. The planned cost savings equivalent to 4% of sales should cover that investment and enable medium term margin growth, the firm said.

RBC said Diageo's sales growth guidance of 2.5% to 3% when it exits 2029 is prudent and consistent with what it considers achievable, although there remains considerable uncertainty around the company's ability to deliver that growth.

RBC maintained its outperform rating on Diageo.

Price: $96.60, Change: $+1.98, Percent Change: +2.09%

Related Articles

Wire

Update: Regal Partners H1 Normalized Earnings, Revenue Up; Shares Fall 7%

(Updates to add stock movement in the headline and the last paragraph)Regal Partners (ASX:RPL) logged AU$0.214 in normalized EPS for the first half, compared with AU$0.105 a year ago, a Monday filing showed.For the six months ended June 30, income from ordinary activities was AU$226.4 million versus AU$128.7 million previously, the Australia-listed alternative investment manager company added.The board declared an interim dividend of AU$0.12 per share, up from AU$0.06 a year earlier, payable Sept. 30 to shareholders on record as of Aug. 31.The company's shares fell around 7% in recent Monday trade.

ASX:RPL
Wire

Philip Morris Reports FDA Authorization for ZYN ULTRA Nicotine Pouches

Philip Morris International (PM) said Friday it has obtained authorization from the US Food and Drug Administration for the marketing of 11 ZYN ULTRA moist oral nicotine pouch products.The firm said the FDA issued Marketing Granted Orders to its US affiliate, Swedish Match USA. Additional 11mg variants are still under scientific review, it added.The authorizations add selection of ZYN ULTRA products to its portfolio of alternatives for adults who smoke or use traditional oral tobacco products, the company said.Price: $188.44, Change: $-3.08, Percent Change: -1.61%

$PM
Wire

Top Cryptocurrencies Jump; Bitcoin Tops $77,000

Major digital assets jumped Friday, with Bitcoin (BTC-USD) topping $77,000.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose 6.4% in the past 24 hours. The Nasdaq 100 and the S&P 500 each gained 0.5%, and the Dow Jones Industrial Average increased 0.8.%.Bitcoin gained 6.1% to $77,122, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume rose 16% to $71.1 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, rose 3.6% to $2,414.XRP (XRP-USD) surged 11%, BNB (BNB-USD) increased 3.7%, and Solana (SOL-USD) added 4%. Dogecoin (DOGE-USD) rose 5.7%, while Cardano (ADA-USD) jumped 11%.The total market value of the cryptocurrency industry rose 5.1% in the past 24 hours to $2.59 trillion, with trading volume gaining 9.2% to $161.4 billion.Price: $77126.61, Change: $+4113.61, Percent Change: +5.63%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD